Omada Health
NASDAQ:OMDAMedical - Healthcare Information Services
+$0.13 today
- Market cap
- $817.04M
- Beta
- 2.09
- P/E (TTM)
- -162.6
- EPS (TTM)
- -$0.11
Volume 1.68M
Average 1.07M
OMDA Interest Expense
Cost of servicing the company's debt during the period.
Omada HealthNASDAQ: OMDA
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $18K fell 98.3% year over year, behind the -66.8% change in trailing-twelve-month interest expense. Sequentially, it rose 38.5% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.
Context
- Interest expense amounted to 1.0% of revenue in FY2025, down 1.7 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.3% toward the trailing-twelve-month pace of -66.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 2.53M USD
- Year-over-year change
- -43.8%
- 3-year CAGR
- -15.5%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.53M | -43.8% |
| FY2024 | 2024-12-31 | 4.51M | -4.2% |
| FY2023 | 2023-12-31 | 4.71M | +12.0% |
| FY2022 | 2022-12-31 | 4.2M | — |
Interest Expense vs competitors
How OMDA compares with its peers on the latest reported figures
- OMDA's LTM Mar 2026 interest expense of $1.48M is the 2nd highest of the 5 companies compared; the peer median is $0.
- Its year-over-year change of -66.8% is the lowest of 2, against a peer median of -19.2%.
- Interest expense amounts to 0.5% of revenue for OMDA, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.32M | -19.2% | -3.5% | 0.8% | |
| LTM Mar 2026 | $1.48M | -66.8% | -15.5% | 0.5% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding OMDA) | $0 | -19.2% | -3.5% | 0.0% | |
Competitors are the stored peer set for OMDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 89.19M | 122.78M | 169.8M | 260.21M |
| Cost of Revenue | 46.39M | 52.81M | 66.92M | 89.27M |
| Gross Profit | 42.79M | 69.97M | 102.88M | 170.94M |
| Gross Margin | 48.0% | 57.0% | 60.6% | 65.7% |
| Research & Development | 26.17M | 33.74M | 35.92M | 40.68M |
| Selling, General & Admin | 88.97M | 102.23M | 110.61M | 142.23M |
| Operating Expenses | 115.14M | 135.97M | 146.53M | 182.91M |
| Depreciation & Amortization | 4.33M | 4.45M | 4.8M | 5.49M |
| EBITDA | (63.99M) | (58.36M) | (37.83M) | (4.75M) |
| EBITDA Margin | -71.7% | -47.5% | -22.3% | -1.8% |
| Operating Income | (72.35M) | (66M) | (43.65M) | (11.97M) |
| Operating Margin | -81.1% | -53.8% | -25.7% | -4.6% |
| Interest Income | 2.2M | 5.78M | 805K | 5.31M |
| Interest Expense | 4.2M | 4.71M | 4.51M | 2.53M |
| Other Income / Expenses | (168K) | (1.51M) | (3.48M) | (806K) |
| Income Before Tax | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Pre-Tax Margin | -81.3% | -55.0% | -27.8% | -4.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Net Margin | -81.3% | -55.0% | -27.8% | -4.9% |
| EPS (Basic) | (1.30) | (1.21) | (0.85) | (0.22) |
| EPS (Diluted) | (1.30) | (1.21) | (0.85) | (0.22) |
| Weighted Avg Shares | 55.74M | 55.74M | 55.74M | 58.43M |
| Weighted Avg Shares (Diluted) | 55.74M | 55.74M | 55.74M | 58.43M |
Omada Health
NASDAQ:OMDA
Intrinsic Alpha fair value
Locked
Current Price
$13.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.